Clinical trial
Analysis of the Efficacy and Safety of Upadacitinib in the Treatment of Refractory Takayasu Arteritis
NCT07500467 is registered in ClinicalTrials.gov with Liu Tian as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Analysis of the Efficacy and Safety of Upadacitinib in the Treatment of Refractory Takayasu Arteritis
- Lead sponsor
- Liu Tian
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 19, 2024
- Completion date
- February 1, 2026
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.